Caribou Biosciences, Inc.

CRBU Nasdaq SEC CIK 1619856
Follow Caribou Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.6M −26.9% vs same quarter last year
Net income −$26.6M +3.4% vs same quarter last year
EPS, diluted −$0.25 +16.7% vs same quarter last year
Operating cash flow −$22.5M +10.6% vs same quarter last year
Revenue by quarter
$2.1M
$2.4M
$2.7M
$2.2M
$3.9M
$2.4M
$1.5M
$1.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$11.2M−$148.1M
FY24$10M−$149.1M
FY23$34.5M−$102.1M
FY22$13.9M−$99.4M
FY21$9.6M−$66.9M
FY20$12.4M−$34.3M
FY19$5.8M−$23.4M
FY18--
MarginsShare of revenue
  • Operating margin
  • Net margin
−2000%−1500%−1000%−500%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−1329.4%−1327.4%
FY24−1667.2%−1491.9%
FY23−336.6%−296.1%
FY22−768.2%−717.8%
FY21−697.8%−697.3%
FY20−292.2%−277.6%
FY19−592.7%−404.8%
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$112.4M
FY24−$143.1M
FY23−$104.9M
FY22−$97.4M
FY21−$34.6M
FY20−$33.5M
FY19−$32.9M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Caribou Biosciences
  • Healthcare median
−1500%−1000%−500%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearCaribou BiosciencesHealthcare median
FY25−1327.4%−30.6%
FY24−1491.9%−47%
FY23−296.1%−58%
FY22−717.8%−80.4%
FY21−697.3%−71.8%
FY20−277.6%−62.2%
FY19−404.8%−46.2%
FY18-−49.6%